[Question] mechanism — what am I missing here
mechanism — what am I missing here. I am not trying to be the "source?" guy. I would just like a source.
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.
gastric emptying slows, it does not stop
The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.
That study was in a rodent model. Worth stating, since the thread has been reading it as human data.
The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.
Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.
Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.
Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.
Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.
Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.
Is there any human data on that mechanism yet?
a mechanism you can state is not a mechanism you have demonstrated
the peripheral and central stories are not in competition
Is there any human data on that mechanism yet?
Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.
Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.
albumin binding is most of the half-life story
GIP is the arm people argue about because the biology is genuinely unsettled
preclinical is not clinical and rodents are not small people
tolerance to the gastric effect develops, appetite effect largely persists
the central appetite effect is doing more work than the gut effect
mechanism explains a direction, not a magnitude
Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.
mechanism explains a direction, not a magnitude
Agreed — and it is why the central and peripheral stories are complementary rather than rival.
What does the discussion section say about the limitation you are glossing?
- 1Is there any human data on that mechanism yet?7 comments in this branch · started by u/ingrid_correia
- 2preclinical is not clinical and rodents are not small people7 comments in this branch · started by u/neha_krastev